Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.40 |
| ▸ | APP | P05067 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945358 | 0.77 | BACE1 (0.58) | BACE1APPKCNH2CTSDALDH1A1 | |
| SCHEMBL932046 | 0.75 | BACE1 (0.60) | BACE1APPKCNH2CTSD | |
| SCHEMBL932309 | 0.75 | BACE1 (0.44) | BACE1APPKCNH2CTSDALDH1A1 | |
| SCHEMBL931308 | 0.73 | BACE1 (0.63) | BACE1APPKCNH2 | |
| SCHEMBL932157 | 0.73 | BACE1 (0.51) | BACE1KCNH2 | |
| SCHEMBL932108 | 0.71 | BACE1 (0.62) | BACE1APPKCNH2CTSD | |
| SCHEMBL932230 | 0.71 | BACE1 (0.59) | BACE1APPKCNH2 | |
| SCHEMBL932111 | 0.71 | BACE1 (0.47) | BACE1APPKCNH2CTSDALDH1A1 | |
| SCHEMBL932757 | 0.71 | BACE1 (0.44) | BACE1APPKCNH2CTSDALDH1A1 | |
| SCHEMBL8225708 | 0.70 | NPSR1 (0.37) | BACE1APPKCNH2CTSDDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |